← Leaderboards
William J Ray
Massachusetts Institute Of Technology
$2,658,897
Attributed
$7,976,690
Total exposure
1
Grants
0
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2020–24$2M$1.5M$1M$500K$0
'20
'21
'22
'23
'24
Funding mix
By agency
NIH$7,976,690 · 1
By mechanism
U01$7,976,690 · 1
Top collaborators
- Alison M Goate5 shared
- Li-Huei Tsai5 shared
Most similar at Massachusetts Institute Of Technology
Same institution · by research overlap
- Stacey Gabriel$366,215,191
- Manolis Kellis$46,984,324
- Christopher B Burge$26,517,219
- David K. Gifford$23,199,191
- Richard O Hynes$17,553,047
Others in their field
Other Emerging Leaders on “Alzheimer&Apos”
- Lance Allen Johnson · University Of Kentucky$7,508,882
- Hyacinth Idu Hyacinth · University Of Cincinnati$6,781,590
- Yi Su · Weill Medical Coll Of Cornell Univ$6,486,733
- Julia Tcw · Icahn School Of Medicine At Mount Sinai$6,079,215
- Jessica Brooke Langbaum · Banner Health$6,050,741
- Timothy Yikai Huang · Sanford Burnham Prebys Medical Discovery Institute$5,936,362
Research focus
Alzheimer&AposAge Of OnsetAgingAdoptedAgreementBiologyCollaborationsAnimalsAffectBasic ScienceBinding ProteinsBiological MarkersCombatBiomarker DevelopmentAmyloid Beta-ProteinBone Marrow HyperplasiaBrainCanis FamiliarisCell LineCell PhysiologyCellsChemistryChip-SeqDisease Progression
Grant awards (5)
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease$1,585,167
U01 · FY2024 · AG
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease$1,584,706
U01 · FY2023 · AG
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease$1,587,671
U01 · FY2022 · AG
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease$1,595,511
U01 · FY2021 · AG
Development of PU.1 Inhibitory Modulators as Novel Therapeutics for Alzheimer's Disease$1,623,635
U01 · FY2020 · AG